GUANGZHOU, China, Sept. 8, 2025 /PRNewswire/ — On August 29, Gushengtang (HKG:2273) announced its interim results for 2025, reporting strong operational and financial performance. The company posted revenue of RMB 1.49 billion, representing a 9.5% year-on-year increase. Net profit grew 41.6% year-on-year to RMB 150 million. The expansion in net profit significantly outpaced top-line growth, reflecting improved profitability and greater operating leverage.
The company also delivered robust cash flow. Operating cash flow reached RMB 300 million, up 111% from the prior year, while free cash flow totaled RMB 210 million, an increase of 466%. The Board declared an interim dividend of RMB 75.766 million, representing a 50% payout ratio. In addition, the company announced a share repurchase program of up to HKD 300 million, demonstrating its commitment to disciplined capital allocation and shareholder returns.
Digital Health Innovation: AI-Enabled Physician Avatars Advance to Commercial Scale
According to the interim report, Gushengtang‘s technology initiatives progressed from pilot programs to full commercial deployment. The company‘s proprietary innovation— an AI-enabled avatar system modeled on leading traditional Chinese medicine (TCM) physicians—has emerged as a new growth driver, addressing structural challenges such as the uneven distribution of specialized expertise across the industry.
Currently, Gushengtang has developed ten primary AI avatars covering eight core TCM specialties. Drawing on the clinical expertise of top practitioners, these digital solutions replicate diagnostic reasoning, treatment methodologies, and prescribing practices. The avatars demonstrate more than 86% alignment with physicians’ decision-making processes. Clinical validation from participating doctors affirms the accuracy and quality of care, enabling providers in remote and international markets to access real-time expert support and improve patient outcomes.
The company’s AI platform now supports patients across the full continuum of care. Prior to …